Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Diabetes Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
BMJ. 2024 Oct 22;387:e080340. doi: 10.1136/bmj-2024-080340.
To assess whether use of glucagon-like peptide-1 (GLP-1) receptor agonists before upper gastrointestinal endoscopy is associated with increased risk of pulmonary aspiration or discontinuation of the procedure compared with sodium-glucose cotransporter-2 (SGLT-2) inhibitors.
Cohort study.
Two deidentified US commercial healthcare databases.
43 365 adults (≥18 years) with type 2 diabetes who used a GLP-1 receptor agonist or SGLT-2 inhibitor within 30 days before upper gastrointestinal endoscopy.
The primary outcome was pulmonary aspiration on the day of or the day after endoscopy, defined using diagnostic codes. The secondary outcome was discontinuation of endoscopy. Risk ratios and corresponding 95% confidence intervals (CIs) were estimated after fine stratification weighting based on propensity score.
After weighting, 24 817 adults used a GLP-1 receptor agonist (mean age 59.9 years; 63.6% female) and 18 537 used an SGLT-2 inhibitor (59.8 years; 63.7% female). Among users of GLP-1 receptor agonists and SGLT-2 inhibitors, the weighted risk per 1000 people was, respectively, 4.15 and 4.26 for pulmonary aspiration and 9.79 and 4.91 for discontinuation of endoscopy. Compared with SGLT-2 inhibitor use, GLP-1 receptor agonist use was not associated with an increased risk of pulmonary aspiration (pooled risk ratio 0.98, 95% CI 0.73 to 1.31), although it was associated with a higher risk for discontinuation of endoscopy (1.99, 1.56 to 2.53).
In this comparative cohort study, no increased risk of pulmonary aspiration during upper gastrointestinal endoscopy was observed among adults with type 2 diabetes using GLP-1 receptor agonists compared with SGLT-2 inhibitors within 30 days of the procedure; however, GLP-1 receptor agonists were associated with a higher risk of discontinuation of endoscopy, possibly owing to a higher risk of retained gastric content. In the absence of evidence from randomized trials, these findings could inform future practice recommendations on the preprocedural protocol for patients requiring endoscopy.
评估在上消化道内镜检查前使用胰高血糖素样肽-1(GLP-1)受体激动剂是否与胃内容物吸入风险增加或内镜检查中断相关,与钠-葡萄糖共转运蛋白-2(SGLT-2)抑制剂相比。
队列研究。
两个美国商业医疗保健数据库。
43365 名(≥18 岁)患有 2 型糖尿病的成年人,他们在接受上消化道内镜检查前 30 天内使用了 GLP-1 受体激动剂或 SGLT-2 抑制剂。
主要结局是内镜检查当天或次日发生的吸入性肺炎,使用诊断代码定义。次要结局是内镜检查中断。根据倾向评分进行精细分层加权后,估计风险比和相应的 95%置信区间(CI)。
加权后,24817 名成年人使用 GLP-1 受体激动剂(平均年龄 59.9 岁;63.6%为女性),18537 名成年人使用 SGLT-2 抑制剂(59.8 岁;63.7%为女性)。GLP-1 受体激动剂和 SGLT-2 抑制剂使用者中,每 1000 人加权风险分别为吸入性肺炎 4.15 和 4.26,内镜检查中断 9.79 和 4.91。与 SGLT-2 抑制剂使用相比,GLP-1 受体激动剂使用与吸入性肺炎风险增加无关(汇总风险比 0.98,95%CI 0.73 至 1.31),但与内镜检查中断风险增加相关(1.99,1.56 至 2.53)。
在这项比较队列研究中,与在接受上消化道内镜检查前 30 天内使用 SGLT-2 抑制剂相比,接受 2 型糖尿病治疗的成年人使用 GLP-1 受体激动剂并未观察到内镜检查期间吸入性肺炎风险增加;然而,GLP-1 受体激动剂与内镜检查中断风险增加相关,可能与胃内容物残留风险增加有关。在缺乏随机试验证据的情况下,这些发现可以为需要内镜检查的患者的术前方案提供未来的实践建议。